and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a…

The Securities issued in the Second Closing have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws. The Company is relying on the exemption from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof. Each Investor provided representations appropriate for a private placement of securities. Restrictive legends are affixed to the Securities issued in the Second Closing. Neither this Current Rep…

Entry into a Material Definitive Agreement. As previously disclosed in its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “Commission”) on September 10, 2025, CAMP4 Therapeutics Corporation (the “Company”) entered into a Securities Purchase Agreement, dated September 9, 2025 (the “Original Agreement”), with certain accredited investors named therein (each, an “Investor” and collectively, the “Investors”), pursuant to which the Company agreed to sell to…

The filing details amendments to equity incentive plans and the adoption of a new inducement plan, which are routine corporate actions.

and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a…

Director — Michael MacLean: The company appointed Michael MacLean as a Class III director and increased the board size from eight to nine members.

and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a…

Entry into a Material Definitive Agreement. On December 22, 2025 (the “Effective Date”), CAMP4 Therapeutics Corporation (the “Company”) and ARE-MA Region No. 59, LLC (“ARE 59”) entered into the First Amendment (the “Lease Amendment”) to the Lease Agreement (the “Cambridge Lease”), dated October 3, 2019, by and between the Company and ARE 59. The term of the Cambridge Lease, which provides for approximately 30,760 square feet of laboratory and office space located at One Kendall Square, Cambri…

of this Current Report on Form 8-K by reference. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CAMP4 THERAPEUTICS CORPORATION By: /s/ Josh Mandel-Brehm Name: Josh Mandel-Brehm Title: President and Chief Executive Officer Date: December 23, 2025

Entry into a Material Definitive Agreement On December 18, 2025, CAMP4 Therapeutics Corporation (the “Company”), entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC (“ Leerink Partners ”), relating to an offering of 5,000,000 shares (the “ Shares ”), of its common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $6.00 per Share. All of the Shares are being sold by the Company. The Company estimates that the net pr…

Entry into a Material Definitive Agreement. On December 17, 2025, CAMP4 Therapeutics Corporation (the “Company”) entered into a Research, Collaboration and License Agreement (the “Agreement”) with GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”). Pursuant to the Agreement, the Company and GSK have agreed to collaborate on the research and development of antisense oligonucleotide (“ASO”) therapeutics targeting regulatory RNAs associated with multiple gene targets relevant to neuro…

Results of Operations and Financial Condition. On November 6, 2025, CAMP4 Therapeutics Corporation issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…

Director — James Boylan, Ravi Thadhani, M.D., Paula Ragan, Ph.D.: Three directors resigned from the board without mention of a successor.

Entry into a Material Definitive Agreement Securities Purchase Agreement On September 9, 2025, CAMP4 Therapeutics Corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors named therein (each, an “ Investor ” and collectively, the “ Investors ”), pursuant to which the Company agreed to sell to the Investors, in up to two closings in a private placement transaction (the “ Private Placement ”). The initial closing o…

Unregistered Sales of Equity Securities. The disclosure regarding the securities to be sold and issued under the Purchase Agreement set forth under

Results of Operations and Financial Condition. On August 14, 2025, CAMP4 Therapeutics Corporation issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…

Results of Operations and Financial Condition. On May 13, 2025, CAMP4 Therapeutics Corporation issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), o…

Results of Operations and Financial Condition. On March 27, 2025, CAMP4 Therapeutics Corporation issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…

Director — Douglas Williams, PhD and Murray Stewart, DM FRCP: The company appointed two new directors to expand the board.

Results of Operations and Financial Condition. On November 21, 2024, CAMP4 Therapeutics Corporation issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…